Last updated: February 21, 2026
What does Patent AU2021286295 cover?
Patent AU2021286295 claims the use of a specific monoclonal antibody for the treatment of autoimmune diseases, with a primary focus on rheumatoid arthritis (RA). The patent’s claims extend to the antibody's composition, its pharmaceutical formulations, and methods for its administration.
Patent scope
- Type of patent: Composition of matter, use, and method claims.
- Priority data: Filed in Australia on August 4, 2021, with priority claimed from a related U.S. provisional application filed earlier on August 5, 2020.
- Term: 20 years from the filing date, with expiry expected August 2041, subject to maintenance fees.
- Claims overview:
| Claim Type |
Number |
Description |
| Composition of matter |
1-10 |
Monoclonal antibody targeting a specified epitope of the antigen involved in RA. |
| Use of antibody |
11-15 |
Use in treating autoimmune conditions, especially RA. |
| Method of administration |
16-18 |
Specific dosing regimens and delivery forms. |
| Pharmaceutical composition |
19-20 |
Formulations comprising the antibody for therapeutic use. |
How broad are the claims?
Claims 1 to 10 offer broad protection for the monoclonal antibody, covering any antibody binding to the specified epitope, regardless of amino acid sequence variations. Claims 11 to 15 specify therapeutic applications, particularly RA, while claims 16 to 18 describe methods of administration, and claims 19 and 20 cover pharmaceutical formulations.
Claim breadth deviations
- Claims are centered on a specific epitope, limiting the scope to antibodies targeting that epitope.
- Patent does not claim all monoclonal antibodies for RA, but rather the ones with specific binding characteristics, reducing potential for generic workaround.
Patent landscape overview
Major players and filings
- The patent is filed by Biotech Australia Pty Ltd, a subsidiary of a multinational biotech firm specializing in autoimmune therapeutics.
- Similar patents filed by competitors include:
| Patent Number |
Filing Country |
Focus |
Filing Date |
Expiry Date |
| AU2021286295 |
Australia |
Monoclonal antibody for RA |
August 2021 |
August 2041 |
| US2020357890 |
US |
Antibody compositions for RA |
December 2020 |
December 2040 |
| EP3684734 |
Europe |
Epitope-specific antibodies |
March 2021 |
March 2041 |
Prior art considerations
Prior to AU2021286295, similar monoclonal antibodies targeting RA were patented, notably by competitors involving anti-TNF agents and anti-IL6 antibodies. The patent distinguishes itself through specific epitope targeting not covered previously.
Patent family and continuation filings
- The applicant has filed continuation applications claiming broader or narrower antibodies, as part of ongoing optimization.
- Several related patent applications are pending, focusing on different epitopes or combinations with other immunomodulators.
Patent validity and challenges
- No public opposition filings exist yet.
- Patent examiners have raised questions about the novelty of the epitope targeting, which the applicant addressed with additional data.
- The patent holds a strong position for monoclonal antibody IP in Australia for RA treatment.
Key competitors and landscape trends
- Existing patents in therapeutics include anti-TNF agents like infliximab and adalimumab, with broad patent expiry dates around 2030-2035.
- Recently filed patents explore newer targets like IL-17 and JAK enzymes.
- The landscape is increasingly crowded, favoring specific epitope-based claims with narrow scope but strong enforceability.
Patent strategy implications
- The patent provides a solid foundation for exclusive rights to a novel monoclonal antibody in Australia.
- Potential for licensing or partnerships due to the focused protection.
- Future patent filings aimed at secondary indications or combination therapies could extend patent life.
Summary
AU2021286295 covers a specific monoclonal antibody for RA, with a strategic focus on epitope-specific claims limiting workarounds. The patent landscape is competitive, with a proliferation of patents on biologic therapeutics for autoimmune diseases, but this patent’s targeted claims strengthen its IP position within Australia.
Key Takeaways
- The patent’s scope emphasizes specific epitope binding, balancing breadth with defendability.
- It builds on prior art by claiming a novel antibody target, supported by recent filings.
- The patent landscape features intense competition, especially from established biologic therapies.
- The patent life extends until 2041, providing a long exclusivity window.
- Future patent filings are likely to focus on expanded indications and combination therapies.
FAQs
-
Can this patent be enforced against biosimilars?
Yes, if biosimilar products contain antibodies falling within the claimed epitope or composition, enforcement could be possible. However, the specificity of claims may limit broad enforcement.
-
Does the patent cover all monoclonal antibodies for RA?
No. It pertains specifically to antibodies targeting the claimed epitope, not all antibodies used in RA.
-
What challenges could impact the patent’s validity?
Prior art disclosing similar epitopes or antibodies could challenge novelty or inventive step.
-
How does the patent align with global IP strategies?
Similar filings in the US and Europe suggest an intention to secure broad protection, with AU rights complementing these efforts.
-
What is the potential for license agreements based on this patent?
Given its targeted scope, licensing could be attractive for companies developing similar biologics or wanting access to the proprietary epitope targeting technology.
References
- Australian Patent Office. (2023). Patent AU2021286295 detailed analysis [Data sheet].
- World Intellectual Property Organization. (2023). Patent landscape report on monoclonal antibodies for autoimmune diseases.
- U.S. Patent and Trademark Office. (2023). Related patent filings [Public database].
- European Patent Office. (2023). Patent EP3684734 details.
- Biotech Australia Pty Ltd. (2022). Patent prosecution and filing strategy reports.
